Health: RSV Immunisation

Baroness Manzoor Excerpts

Wednesday 17th January 2024 Lords Chamber

[Lord Markham (Con)]

First, I thank the noble Baroness. She has been a tireless campaigner on this issue and very good—quite rightly—at holding our feet to the fire. The exciting news is that the new vaccines that are coming along for both mothers and infants, as well as the over-75s, are now cost effective; that was recognised in the JCVI’s analysis. As part of that, we have plans to fund the programme, as mentioned. I would rather not go into the details of the actual budgets, because they depend on the tender and I do not want to give that information out to the market—but I can reassure the noble Baroness that plans are in place.

[Baroness Manzoor (Con)]

My Lords, RSV is a leading cause of infant mortality globally. Sadly, as my noble friend the Minister will know, 20 to 30 such deaths occur in the UK. I am pleased to hear about the progress that the Government are making to roll out the programme in the UK, but my noble friend will know that rolling out this programme will significantly reduce costs to the NHS by reducing GP visits, reducing attendance at A&E and reducing the 20,000 hospitalisations of infants aged under one year. Can my noble friend the Minister say, as we move towards autumn 2024 and the rollout of the vaccination programme, what the Government are doing to ensure that mothers and families know about the programme so that they can take up this vaccination when it is available?

[Lord Markham (Con)]

As I mentioned, the tender is in place with a view to rolling it out in the autumn. Whether we go for the maternal vaccination or the infant one will depend on the communication plan, but I can assure my noble friend that a communication plan will be part of this ground-breaking rollout. Only one other public health rollout like this has happened in the world—in Galicia, Spain—so I am proud to say that we will be top of the list.